NFHHMUi001-A
General
Cell Line |
|
| hPSCreg name | NFHHMUi001-A |
| Cite as: | NFHHMUi001-A (RRID:CVCL_C1V1) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi045-A (GBA L444P(CBIGi045-A), IPSC0077) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi049-A (IPSC0093, SOD1 I144T(CBIGi049-A)) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis |
| Last update | 16th June 2022 |
| User feedback | |
Provider |
|
| Generator | Department of Neurosurgery of The First Affiliated Hospital of Harbin Medical University (NFHHMU) |
External Databases |
|
| BioSamples | SAMEA13602499 |
| Cellosaurus | CVCL_C1V1 |
| Wikidata | Q114312505 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Han |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA14251112 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | 哈尔滨医科大学附属第一医院临床研究管理委员会(Clinical Research Management Committee of the First Affiliated Hospital of Harbin Medical University) |
| Approval number | 2020IIT038 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A sample of peripheral blood mononuclear cells.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Other medium:
Base medium: Nuwacell ncTarget hPSC Medium
Main protein source: Serum concentration: % |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.